Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp>
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> is a paper indexed in PICO Portal from OpenAlex.
How many citations does Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> have?
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> has 24 citations in the OpenAlex counts PICO Portal stores.
When was Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> published?
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> has 2022 year in the PICO Portal index.
What is the open-access status of Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp>?
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> has closed oa status in the PICO Portal index.
What is the DOI of Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp>?
The DOI for Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> is on the source record.
What is the PMID of Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp>?
The PMID for Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> is on the source record.
What is the OpenAlex record for Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp>?
The OpenAlex for Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with <scp>EGFR G719X</scp>/<scp>L861Q</scp>/<scp>S768I</scp> is on the source record.